Levovax OZ Tablet is a combination antibiotic formulation containing Levofloxacin 250 mg and Ornidazole 500 mg, designed for the treatment of a broad spectrum of bacterial and protozoal infections. Levofloxacin, a fluoroquinolone antibiotic, exerts its bactericidal effect by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for DNA replication, transcription, repair, and recombination. Ornidazole, a nitroimidazole derivative, is effective against anaerobic bacteria and protozoa by disrupting DNA synthesis and causing strand breakage. This synergistic combination is indicated for mixed infections involving aerobic and anaerobic bacteria, including respiratory tract infections, urinary tract infections, gastrointestinal infections, pelvic inflammatory disease, and certain protozoal infections such as amoebiasis and giardiasis. Levovax OZ Tablet should be administered as prescribed by a healthcare professional, with dosage adjustments based on the severity of infection, renal function, and patient response. Caution is advised in patients with a history of hypersensitivity to fluoroquinolones or nitroimidazoles, and potential side effects include gastrointestinal disturbances, CNS effects, and hypersensitivity reactions. It is contraindicated in pregnancy and lactation unless deemed necessary by a physician. Proper adherence to the prescribed regimen is essential to prevent resistance development and ensure therapeutic efficacy.